Leading Critical
Care Solutions

Tenax Therapeutics is focused on identifying, developing and commercializing products for the critical care market.

In the U.S. alone, more than five┬ámillion hospitalized patients are treated in an intensive care setting annually according to the Society of Critical Medicine.    


The LEVO-CTS trial results were presented on

Sunday, March 19, 2017, at the

American College of Cardiology

66th Annual Scientific Session in Washington, D.C.

Primary Results Presentation

Focus on Critical Care

Given the high mortality, morbidity, and costs associated with the treatment of many intensive care patients, we believe that there is a substantial opportunity to add value for patients, physicians, hospitals, and ultimately shareholders.